Abciximab

Abciximab Reactions 1664, p13 - 12 Aug 2017 Acute profound thrombocytopenia: case reports A 53-year-old man developed acute profound thrombocytopenia during therapy with abciximab [route and dosage not stated]. The man with acute chest pain was diagnosed with non ST elevation myocardial infarction. Subsequently, he underwent percutaneous coronary intervention with abciximab infusion and heparin. However, he developed acute profound thrombocytopenia. His platelet count was notes as less than 20000/L within nine hours of abciximab infusion [outcome not stated]. Author comment: "Abciximab (c7E3 Fab) is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. However, major side effects have been reported with its use including hypotension, major bleeding and thrombocytopenia." Golden T, et al. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Reports 2017: 221182, Jan 2017. Available from: URL: http://doi.org/10.1136/bcr-2017-221182 [Summarised from an abstract] - USA 803262699 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Abciximab

Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/abciximab-YIf80tvOOf
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-34293-0
Publisher site
See Article on Publisher Site

Abstract

Reactions 1664, p13 - 12 Aug 2017 Acute profound thrombocytopenia: case reports A 53-year-old man developed acute profound thrombocytopenia during therapy with abciximab [route and dosage not stated]. The man with acute chest pain was diagnosed with non ST elevation myocardial infarction. Subsequently, he underwent percutaneous coronary intervention with abciximab infusion and heparin. However, he developed acute profound thrombocytopenia. His platelet count was notes as less than 20000/L within nine hours of abciximab infusion [outcome not stated]. Author comment: "Abciximab (c7E3 Fab) is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. However, major side effects have been reported with its use including hypotension, major bleeding and thrombocytopenia." Golden T, et al. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Reports 2017: 221182, Jan 2017. Available from: URL: http://doi.org/10.1136/bcr-2017-221182 [Summarised from an abstract] - USA 803262699 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664

Journal

Reactions WeeklySpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off